Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PsyPal
NCT06782724Phase 2Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jul 2025
- Primary completion
- Jan 2027
- Modality
- Orthosteric Ligands
- Countries
- 4
01
Overview
A Phase 2 trial of psilocybin in major depressive disorder (MDD), sponsored by University Medical Center Groningen. Started Jul 2025; status: recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06782724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06782724.